Today, the Board of Directors of Sorin S.pA. (MIL:SRN) met and
approved the following decisions:
-- Professor Umberto Rosa was confirmed as Chairman and was given
all executive powers for ordinary course of business
-- Luca Di Giacomo was named Vice-Chairman with the role of
coordinating the activities of the Chairman and the various committees
in the Group to define the business strategies going forward
-- An executive committee was established headed by the Chairman
and composed of the following Members of the Board: Paolo Braghieri,
Luca Di Giacomo, Ettore Lonati and Claudio Zulli; they will offer
advice to the Chairman and the Board of Directors regarding decisions
for the Group.
Further, a management committee was established headed by Umberto
Rosa. It is composed of four top managers from the Sorin Group. The
objective of this committee is to guarantee effective management of
the business areas and to ensure economic and financial objectives for
the current year are met.
The Board also appointed two advisory committees: a Compensation
Committee composed of Michele Cappone, Enrico Consoli and Marco
Trabucchi and an Internal Audit Committee composed of Enzo Nicoli,
MIchele Cappone and Andrea Mattarelli.
The Board of Directors also decided to review and propose a Stock
Option plan to shareholders in the near future.
About the Sorin Group:
The Sorin Group (Bloomberg: SRN.IM; Reuters: SORN.MI), a world
leader in the development of medical technologies for cardiac surgery,
offers innovative therapies for cardiac rhythm dysfunctions,
interventional cardiology and the treatment of chronic kidney
diseases. The Sorin Group includes: Dideco, CarboMedics, Inc., COBE
Cardiovascular, Inc., Stockert, Mitroflow, ELA Medical, Inc., Sorin
Biomedica, Bellco and Soludia. It has more than 4,500 employees
working at facilities in more than 80 countries throughout the world
to serve over 5,000 public and private treatment centers. For more
information, please visit: www.sorin.com
